2014 Fiscal Year Final Research Report
Serum biomarker for digestive cancer
| Project/Area Number |
23591971
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Showa University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2011-04-28 – 2015-03-31
|
| Keywords | Ｖｉｍｅｎｔｉｎ / Ｍｅｔｈｙｌａｔｉｏｎ |
|---|
| Outline of Final Research Achievements |
The present study aimed to examine the feasibility of detecting vimentin (VIM) methylation in the serum of patients with colorectal cancer (CRC) and to determine the effectiveness of a relatively simple, inexpensive, and noninvasive test performed in combination with the conventional carcinoembryonic antigen analysis. Patients and Methods： VIM methylation in the serum DNA of 242 patients with CRC was measured by a quantitative methylation-specific polymerase chain reaction. Results: A significantly higher positive rate was obtained for VIM methylation than for carcinoembryonic antigen or carbohydrate antigen 19-9 in stage 0, I, and II patients. The combination of all three markers yielded similar sensitivity for patients with disease of stage 0: 57.1%, I: 36.1%, II: 45.2%, and III: 55.4%, whereas the sensitivity reached 85.7% for patients with stage IV disease. Conclusion: VIM methylation of serum DNA may be a useful marker for early detection of CRC.
|
| Free Research Field |
消化器外科（大腸肛門病）
|
